Provided by Tiger Trade Technology Pte. Ltd.

Adial Pharmaceuticals

0.2405
-0.0213-8.14%
Post-market: 0.2388-0.0017-0.71%19:58 EST
Volume:519.73K
Turnover:131.70K
Market Cap:6.41M
PE:-0.34
High:0.2664
Open:0.2600
Low:0.2405
Close:0.2618
52wk High:1.30
52wk Low:0.2200
Shares:26.65M
Float Shares:26.54M
Volume Ratio:1.43
T/O Rate:1.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7013
EPS(LYR):-2.7203
ROE:-155.01%
ROA:-79.36%
PB:1.42
PE(LYR):-0.09

Loading ...

Adial Pharmaceuticals announces $2.86M warrant inducement transaction

TIPRANKS
·
Nov 26

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds

GlobeNewswire
·
Nov 26

Strategic Advancements and Collaborations Propel Adial Pharmaceuticals’ Buy Rating

TIPRANKS
·
Nov 19

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 17

Adial Pharmaceuticals reports Q3 net loss of $1.8 million

Reuters
·
Nov 14

Adial Pharmaceuticals Q3 Net Income USD -1.8 Million

THOMSON REUTERS
·
Nov 14

Adial Pharmaceuticals: Implementing FDA's Recommendations Based on Eop2 Meeting, to Advance Ad04 Toward Phase 3 Development

THOMSON REUTERS
·
Nov 14

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 14

Adial Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview

Reuters
·
Nov 07

Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show

GlobeNewswire
·
Oct 17

Strategic Advancements and Genetic Testing Propel Adial Pharmaceuticals to a Buy Rating

TIPRANKS
·
Oct 11

Adial Pharmaceuticals partners with Genomind for Precision Medicine Testing

TIPRANKS
·
Oct 09

Adial Pharmaceuticals Raised to Buy From Hold by Maxim Group

Dow Jones
·
Sep 30

Adial Pharmaceuticals Inc : Maxim Group Raises to Buy From Hold

THOMSON REUTERS
·
Sep 30

Adial Pharmaceuticals upgraded to Buy from Hold at Maxim

TIPRANKS
·
Sep 30

Adial Pharmaceuticals Advances AD04 with FDA Support

TIPRANKS
·
Sep 16

Adial Pharmaceuticals Provides Business Update Following Favorable Comments From FDA End-of-Phase 2 (Eop2) Meeting for Ad04

THOMSON REUTERS
·
Sep 16

Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04

GlobeNewswire
·
Sep 16

Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule

GlobeNewswire
·
Sep 03

Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments

GlobeNewswire
·
Aug 20